Adverse events · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye
1 finding from 1 review
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye
1 finding from 1 review
Adverse events · preterm infants with apnea
1 finding from 1 review
2
2 participants
GRADE not reported
Adverse events (n/N) · Adults or children with overweight or obesity
1 finding from 1 review
Adverse events (n/N) · Adults or children with overweight or obesity
1 finding from 1 review
Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
1 finding from 1 review
Adverse events · Children who were regular dental attenders with caries-free first or second primary molars (public health service clinic, Brazil)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · venous leg ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in adverse events compared with higher dose (low certainty).
1 finding from 1 review
Adverse events ( · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Adverse events · people with pressure ulcers
Alginate dressing followed by hydrocolloid dressing showed no clear difference in adverse events compared with hydrocolloid dressing alone (low certainty).
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review